Prognostic Factors, Treatment, and Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab (R) Era

被引：0
|
作者：
Hiniker, S. M. [1 ]
Pollom, E. L. [1 ]
Khodadoust, M. S. [1 ]
Kozak, M. M. [1 ]
Advani, R. H. [1 ]
Hoppe, R. T. [1 ]
机构：
[1] Stanford Univ, Stanford, CA 94305 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2014年 / 90卷
关键词：
D O I：
10.1016/j.ijrobp.2014.05.1993
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3185
引用
收藏
页码：S677 / S678
页数：2
相关论文
共 50 条
  • [41] Prognostic factors in diffuse large B-cell lymphoma
    Niitsu, Nozomi
    INTERNAL MEDICINE, 2006, 45 (05) : 227 - 228
  • [42] IS THERE A ROLE FOR INVOLVED NODAL RADIOTHERAPY IN THE MANAGEMENT OF LIMITED STAGE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)?
    Campbell, B.
    Connors, J.
    Gascoyne, R.
    Pickles, T.
    Morris, J.
    Sehn, L.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S16 - S17
  • [43] Primary breast diffuse large B-cell lymphoma in the era of rituximab
    Zhang, Na
    Cao, Caineng
    Zhu, Yuan
    Liu, Peng
    Liu, Luying
    Lu, Ke
    Luo, Jialin
    Zhou, Ning
    ONCOTARGETS AND THERAPY, 2016, 9 : 6093 - 6097
  • [44] Limited-Stage Diffuse Large B-cell Lymphoma in Head and Neck Treated With CHOP or Rituximab-CHOP (R-CHOP) Plus Radiation Therapy
    Ohga, S.
    Nakamura, K.
    Shioyama, Y.
    Sasaki, T.
    Nonoshita, T.
    Yoshitake, T.
    Asai, K.
    Hirata, H.
    Honda, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S618 - S618
  • [45] Outcomes of primary and secondary breast diffuse large B-cell lymphoma in rituximab-era
    Nishimura, Noriko
    Nishihara, Anna
    Inoue, Norihito
    Marshall, Shoko
    Yamauchi, Hirofumi
    Kusano, Yoshiharu
    Mishima, Yuko
    Yokoyama, Masahiro
    Hatake, Kiyohiko
    Terui, Yasuhito
    ANNALS OF ONCOLOGY, 2018, 29
  • [46] Rituximab, gemcitabine, cisplatin, and methylprednisolone (R-GEM-P) in treatment of relapsed diffuse large B-cell lymphoma (DLBCL).
    Barton, Sarah Rachel
    Hawkes, Eliza Anne
    Cunningham, David
    Peckitt, Clare
    Chua, Sue
    Wotherspoon, Andrew
    Attygalle, Ayoma
    Horwich, Alan
    Dearden, Claire E.
    Potter, Mike
    Chau, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story
    Bari, A.
    Marcheselli, L.
    Sacchi, S.
    Marcheselli, R.
    Pozzi, S.
    Ferri, P.
    Balleari, E.
    Musto, P.
    Neri, S.
    Spiriti, M. A. Aloe
    Cox, M. C.
    ANNALS OF ONCOLOGY, 2010, 21 (07) : 1486 - 1491
  • [48] Clinical Prognostic Models in Diffuse Large B-Cell Lymphoma Patients Are Still Essential in the Rituximab Era
    de Padua Covas Lage, Luis Alberto
    Costa, Renata Oliveira
    Hallack Neto, Abrahao Elias
    Siqueira, Sheila
    Santucci, Rodrigo
    de Paula, Henrique Moura
    Pereira, Juliana
    BLOOD, 2014, 124 (21)
  • [49] Caspase 3a: new prognostic marker for diffuse large B-cell lymphoma in the rituximab era
    Provencio, Mariano
    Martin, Paloma
    Garcia, Vanesa
    Candia, Antonio
    Sanchez, Antonio C.
    Bellas, Carmen
    LEUKEMIA & LYMPHOMA, 2010, 51 (11) : 2021 - 2030
  • [50] Serum B-cell activating factor (BAFF) in diffuse large B-cell lymphoma: Its prognostic significance in the rituximab era
    Kim, Seok Jin
    Sung, Hwa Jung
    Choi, Chul Won
    Kim, In Sun
    Kim, Byung Soo
    Yoon, Soo-Young
    Won, Jong-Ho
    Kim, Jun Suk
    BLOOD, 2007, 110 (11) : 470A - 471A
12345